

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Shu-Ping Yang et al.

ANTI-CHRONDROSARCOMA COMPOUNDS

Docket No.: Filed:

1443.064US1

Examiner:

June 20, 2003

Customer No.: 21186

Unknown

Serial No.: 10/601,059

Due Date: N/A

Group Art Unit: 1646

Confirmation No.: 5526

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

We are transmitting herewith the following attached items (as indicated with an "X"):

<u>X</u> A return postcard.

An Information Disclosure Statement (2 pgs.), Form 1449 (9 pgs.), and copies of 140 cited documents.

If not provided for in a separate paper filed herewith, Please consider this a PETITION FOR EXTENSION OF TIME for sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

Customer Number 21186

Atty: Robin A. Chadwick

Reg. No. 36,477


CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 200 day of November, 2003.

Gulim Abilova Name

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

Customer Number 21186 (GENERAL)





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Serial No.: Shu-Ping Yang et al.

10/601,059

June 20, 2003

Examiner:

Unknown

Group Art Unit: 1646

1443.064US1

Filed: Title:

ANTI-CHRONDROSARCOMA COMPOUNDS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 et. seq., the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Note that several Japanese Patent numbers are cited on the 1449 form. Pursuant to 37 C.F.R. § 1.98 (a)(3)(ii), an English abstract for each is being submitted herewith. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Information Disclosure Statement considered.

INFORMATION DISCLOSURE STATEMENT

Serial No :10/601059 Filing Date: June 20, 2003

Title: ANTI-CHRONDROSARCOMA COMPOUNDS

Dkt: 1443.064Ŭ\$1

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

SHU-PING YANG ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A. P.O. Box 2938

Minneapolis, MN 55402

(516) 795-6820

Reg. No. 36,477

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 2002 day of November, 2003.

Spelim abilova

PTO/SB/084(10-01)
Approved for use through 10/31/2002, OMB 651-0031
US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE
on of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many speets as necessary)

٧	2 4 2003	ACE TO
T	~	
R_{ℓ}	DEMAN	
	Sheet 1	of 9

10/601,059
June 20, 2003
Yang, Shu-Ping
1646
Unknown

Attorney Docket No: 1443.064US1

	· · · · · · · · · · · · · · · · · · ·	US PA	ATENT DOCUMENT	S		
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
	US-4,424,552	01/03/1984	Marcoux, Roland S.	361	306	05/28/1982
	US-5,270,447	12/14/1993	Liotta, Lance A., et al.	530	326	03/01/1989
	US-5,280,106	01/18/1994	Liotta, Lance A., et al.	530	330	02/26/1990
	US-5,372,809	12/13/1994	Liotta, Lance A., et al.	424	185.1	01/31/1992
	US-5,585,356	12/17/1996	Liotta, Lance A., et al.	514	17	08/12/1994
	US-5,698,671	12/16/1997	Stetler-Stevenson, William G., et al.	530	324	08/02/1994
	US-5,770,691	06/23/1998	Fields, Gregg B., et al.	530	328	06/05/1995
	US-5,811,252	09/22/1998	Verheijen, Johan H.	435	23	07/06/1995
	US-5,869,277	02/09/1999	Stetler-Stevenson, William G., et al.	435	28	11/08/1991
	US-6,043,087	03/28/2000	Bini, Alessandra, et al.	435	337	07/25/1997
	US-6,127,139	10/03/2000	Te Koppele, Johannes Maria, et al.	435	24	01/02/1997
	US-6,191,225	02/20/2001	Barkac, Karen A., et al.	525	208	08/16/1999
	US-6,204,043	03/20/2001	Steven, Steven D.	435	226	03/01/1995
	US-6,274,703	08/14/2001	Goldberg, Gregory I.	530	324	08/24/1998
	US- 2001/0016333 A1	08/23/2001	Seiki, Motoharu, et al.	435	69.1	12/12/2000
	US- 2001/0031478 A1	10/18/2001	Bronstein, Irena, et al.	435	7.5	03/28/2001

		FOREIGN PATEN	IT DOCUMENTS			
Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T²
_	EP-0917165	05/19/1999	Yasuyuki, Naito, et al.	H01 G	4/30	
_	JP-06213888A	05/05/1994	Okada, Yasunori, et al.	G01 N	33/53	
_	JP-06300757A	10/28/1994	Hayakawa, Taro, et al.	G01 N	33/53	
	JP-07159402A	06/23/1995	Tani, Hisanori , et al.	G01 N	33/53	
-	JP-08134098A	05/28/1996	Kuroda, Kazuhiko, et al.	C07K	16/18	

EXAMINER

DATE CONSIDERED

PTO/SB/08A(10-01)
Approved for use through 10/31/2002, OMB 651-0031
US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE
on of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use as many sheets us necessary)

Complete if Known **Application Number** 10/601,059 June 20, 2003 Filing Date **First Named Inventor** Yang, Shu-Ping **Group Art Unit** 1646 Unknown **Examiner Name**

Sheet 2 of 9

NOV 2 4 2003 \$

Attorney Docket No: 1443.064US1

· · · ·		FOREIGN PATEN	T DOCUMENTS			
Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T ²
	JP-08136548A	05/31/1996	Kuroda, Kazuhiko, et al.	G01 N	33/574	
	JP-08217800A	08/27/1996	Okada, Yasunori, et al.	C07K	16/40	
7	JP-09023889A2	01/28/1997	Sedlacek, Hans-Harald, et al.	C12 N	15/09	
-	JP-09084589A	03/31/1997	Seiki, Motoharu, et al.	C12 N	15/09	
	JP-09087299A	03/31/1997	Shinagawa, Akira, et al.	C07K	16/40	
	JP-09136841A	05/27/1997	Politi, Vincento, et al.	A61K	45/00	
/	JP-09206099A	08/12/1997	Kobayashi, Koji , et al.	C12 Q	1/28	
	JP-09249700	09/22/1997	Liotta, Lance A., et al.	C07K	14/81A	
	JP-10210982A	08/11/1998	Seiki, Motoharu, et al.	C12 N	15/09	
_	JP-10287700A	10/27/1998	Okada, Ysunori, et al.	C07K	16/40	
_	JP-10313896A	12/02/1998	Kano, Hiroyuki, et al.	C12 Q	1/37	
_	JP-2000270874A	10/03/2000	Lopez-Otin, Carlos, et al.	C12 N	15/09	
$\overline{}$	JP-2001011093A2	01/16/2001	Liotta, Lance A., et al.	C07K	7/08	
./	WO-99/31969	07/01/1999	Neuhold, Lisa A., et al.	A01K		
	WO-00/20860	04/13/2000	Joyce, Alison, et al.	G01 N	33/53	
-	WO-00/63227 —	10/26/2001	Zhu, Yuan, et al.	C07 H	21/04	
	WO-01/10437	02/15/2001	Partridge, Nicola C.	A61K	31/35	
	WO-01/38558 A2	05/31/2001	Wakelam, Michael J., et al.	C12 Q	1/00	
	WO-01/62206	08/30/2001	Hazan, Rachel B.	A61K		
_	WO-01/62261	08/30/2001	Richards, Andrew J., et al.	A61K	31/65	
	WO-90/10228	09/07/1990	Liotta, Lance A., et al.	G01 N33	543	
	WO-94/10208	05/11/1994	Ahrens, Diane, et al.	C07K	15/28	
	WO-96/18725	06/20/1997	Greene, John M., et al.	C12 N	1/21	
_	WO-97/25437	07/17/1997	Te Koppele, Johannes M., et al.	C12 Q	1/37	
,	WO-98/04287	02/05/1998	Foged, Niels T., et al.	A61K	39/395	
~-	WO-98/12309 -	03/26/1998	Goldberg, Gregory I.	C12 N	9/64	

EXAMINER

DATE CONSIDERED

PTC/SB/08A(10-01)
Approved for use through 10/31/2002, OMB 651-0031
US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE
older the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO
INFORMATION DISCLOSURE Complete if Known 10/601,059 **Application Number** TATEMENT BY APPLICANT June 20, 2003 **Filing Date** Yang, Shu-Ping **First Named Inventor Group Art Unit** 1646 Unknown **Examiner Name** Attorney Docket No: 1443.064US1

		FOREIGN PATEN	IT DOCUMENTS			
Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T ²
	WO-98/31818	07/23/1998	Ni, Jian, et al.	C12 N	15/57	
_	WO-98/40475	09/17/1998	Falduto, Michael, et al.	C12 N	9/64	
	WO-98/42865	10/01/1998	Lopata, Alexander, et al.	C12 Q	1/37	
	WO-99/05261	02/04/1999	Bini, Alessandra, et al.	C12 N	5/06	
/	WO-99/65519	12/23/1999	Treadwell, Benjamin V., et al.	A61K	39/00	

	OTHER	DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	_	AGREN, MAGNUS S., "Matirx metalloproteinases (MMPs) are required for reepitheliazation of cutaneous wounds", <u>Archives Dermatol. Res., 291,</u> (1999), 583-590	
	<u>-</u>	ATTIE, KENNETH M., "Genetic studies in idiopathic short stature", Current Opinion in Pediatrics, 12, (2000), 400-404	
	_	AZZAM, H. S., et al., "Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production", J. Natl. Cancer Inst., 85 (21), (1993),1758-1764	
	_	BAKER, E. A., et al., "Proteinases, their inhibitors, and cytokine profiles in acute wound fluid", Wound Repair Regen., 8 (5), (2000), 392-398	
		BECKER, JOSEPH W., "Stromelysin-1: Three-dimensional structure of the inhibited catalytic domain and of the C-truncated proenzyme", <u>Protein Science</u> , <u>4</u> , (1995), 1966-1976	
	_	BEREND, KEITH R., et al., "Association between ratio of matrix metalloproteinase-1 to tissue inhibitor of metalloproteinase-1 and local recurrence, metastasis, and survival in human chondrosarcoma", <u>Journal of Bone & Joint Surgery - American Volume</u> . 80(1), (1999), 893-895	
	1	BHIDE, V. M., et al., "Use of a fluorogenic septapeptide matrix metalloproteinase assay to assess responses to periodontal treatment", <u>J. Periodontol.</u> , 71(5), (2000), 690-700	
	_	BICKETT, D. M., et al., "A high throughput fluorogenic substrate for interstitial collagenase (MMP-1) and gelatinase (MMP-9)", <u>Anal. Biochem., 212 (1)</u> , (1993), 58-64	
		BICKETT, D. M., et al., "A high throughput fluorogenic substrate for stromelysin (MMP-3)", Ann. N Y Acad. Sci., 732, (1994), 351-355	
	_	BLASCHKE, RUDIGER J., et al., "SHOX: Growth, Leri-Weill and Turner Syndromes", TEM, 11, (2000), 227-230	

PTO/SB/08A(10-01)
Approved for use through 10/31/2002, OMB 651-0031
US Patent & Trademerk Office: U.S. DEPARTMENT OF COMMERCE
officer the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO Complete if Known INFORMATION DISCLOSURE STATEMENT BY APPLICANT 10/601,059 **Application Number** June 20, 2003 **Filing Date** Yang, Shu-Ping **First Named Inventor Group Art Unit** 1646 Unknown **Examiner Name** Attorney Docket No: 1443.064US1

	OTHER	DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	_	BREMER, C., et al., "In Vivo molecular toarget assessment or matrix metaloproteinase inhibition", Nat. Med., 7 (6), (2001), 743-748	
	_	BROWN, P. D., et al., "Cellular activation of the 72 kDa type IV procollagenase/TIMP-2 complex", Kidney Int., 43 (1), (1993), 163-170	
		BROWN, REBECCAH L., et al., "PDGF and TGF-a Act Synergistically to	
		Improve Wound Healing in the Genetically Diabetic Mouse", <u>Journal of</u> <u>Surgical Research, 56,</u> (1994), 562-570	
	_	BROWNER, MICHELLE F., "Matrilysin-Inhibitor Complexes: Common Themes among Metalloproteases", <u>Biochemistry</u> , 34, (1995), 6602-6610	
		CABRELE, CHIARA, et al., "Y-receptor affinity modulation by the design of pancreatic", Peptides, 22, (2001), 365-378	
	-	CALABRESE, EDWARD J., "Cell Migration / Chemotaxis: Biphasic Dose Responses", Critical Reviews in Toxicology, 31 (4&5), (2001), 615-624	
	<u>~:</u>	CALVIN, MELISSA, "Cutaneous Wound Repair", Wounds: A Compendium of Clinical Research and Practice, 10 (1), (1998), 12-32	
		CHEN, L. C., et al., "Disruption of the cysteine-75 and zinc ion coordination is not sufficient to activate the precursor of human matrix metalloproteinase 3 (stromelysin 1)", Biochemistry, 32 (39), (1993), 10289-10295	
		CHI, YEON SOOK, et al., "Effects of the Chestnut Inner Shell Extract on the Expression of Adhesion Molecules, Fibronectin and Vitronectin, of Skin Fibroblasts in Culture", <u>Archives of Pharmacal Research</u> , 25 (4), (2002), 469-474	
		CHIN, JASON W., et al., "Concerted Evolution of Structureand Function in a Miniature Protein", J. Am. Chem. Soc., 123, (2001), 2929-2930	
		CHIN, JASON W., et al., "Methodology for Optimizing Functional Miniature Proteins Based on Avian Pancreatic Polypeptide Using Phage Display", Bioorganic & Medicinal Chemistry Letters, 1, (2001), 1501-1505	
		CLARK, RICHARD A., "Wound Repair", The Molecular and Cellular Bilogy of Wound Repair - 2nd ed., Plenum Press, NY, (1995), 3-50	
		COLANDREA, TERESA DI, "Epidermal Expression of Collagenase Delays Wound-Healing in Transgenic Mice", The Journal of Investigative Dermatology, (1998), 1029-1033	
		DUIVENVOORDEN, WILHELMINA C., "Use of Tetracycline as an Inhiitor of Matrix Metalloproteinase Activity Secreted by Human Bone-Metastasizing Cancer Cells", Invasion Metastasis, 17, (1997), 312-322	
		DUNCAN, M. E., et al., "Human matrix metalloproteinase-9: activation by limited trypsin", Eur. J. Biochem., 258 (1), (1998), 37-43	
		FARMER, W. H., et al., "A continuous fluorescent assay for measuring protease activity using natural protein substrate", <u>Anal. Biochem., 197 (2)</u> , (1991), 347-352	
		FERNANDEZ-CATALAN, CARLOS, "Crystal structure of the complex formed	

PTO/SB/08A(10-01)
Approved for use through 10/31/2002, OMB 651-0031
US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE
Office the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO Complete if Known INFORMATION DISCLOSURE **Application Number** 10/601,059 TATEMENT BY APPLICANT June 20, 2003 Filing Date y sheets as necessary) Yang, Shu-Ping **First Named Inventor Group Art Unit** 1646 Unknown **Examiner Name** Attorney Docket No: 1443.064US1

	OTHER	DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of	
		metalloproteinases-2, the soluble progelatinase A receptor", The EMBO	
		<u>Journal, 17 (17),</u> (1998), 5238-5248	ļ
		FREIJE, J. J., et al., "Molecular cloning and expression of collagenase-3, a	
		novel human matrix metalloproteinase produced by breast carcinomas", <u>J.</u>	
		Biol. Chem., 269 (24), (1994), 16766-16773	<u> </u>
		FREIRE, E., et al., "Calorimentrically Determined Dynamics Of Complex	
		Unfolding Transitions in Proteins", Annual Review of Biophysics and	
		Biophysical Chemistry, 19, (1990), 159-188	
		GARBETT, E. A., et al., "Proteolysis in human breast and colorectal cancer",	
		Br. J. Cancer, 81 (2), (1999), 287-293	
		GOMIS-RUTH, FRANZ-XAVER, "Mechanism of inhibition of the human matrix	
		metalloproteinase stromelysin-1 by TIMP-1", Letters to Nature, 389, (1997),	
		77-81	
		GRAMS, FRANK, "X-ray structures of human neutrophil collagenase	
		complexed with peptide hydrozamate and peptide thiol inhibitors", European	
		Journal of Biochemistry, 228, (1995), 830-841	
		GUEX, NICOLAS, "Swiss-MODEL and the Swiss-Pdb Viewer: An	
		environment for comparative protein modeling", <u>Electrophesis</u> , 18, (1997),	
		2714-2723	
		HIGGINS, DESMOND G., "Clustal V: improved software for multiple	
		sequence alignment", Computer applications in the biosciences, 8 (2), (1992),	
		189-191	
		HILPERT, KAI, et al., "Characterizing and Optimizing Protease/Peptide	
		Inhabitor Interactions", <u>J. Biochem., 128,</u> (2000), 1051-1057	
İ		HOLLIS, THOMAS, et al., "Structure of the gene 2.5 protein, a single-stranded	
		DNA binding", Department of Biological Chemistry and Molecular	
		Pharmacology, (2001), 9557-9562	
		HOWARD, ERIC W., "Preferential Inhibition of 72- and 92-kDa Gelatinases by	
		Tissue Inhibitor of Metalloproteinases-2", The Journal of Biological Chemistry,	
		<u>266 (20), (1991), 13070-13075</u>	
		HUANG, WEN, "Folding and characterization of the amino-terminal domain of	1
		human tissue inhibitor of metalloproteinases-1 (TIMP-1) expressed at high	
		yield in E. coli", <u>FEBS Letters, 384,</u> (1996), 155-161	
		ITOH, M., et al., "Flow injection analysis for measurement of activity of matrix	1
		metalloproteinase-7 (MMP-7)", J. Pharm. Biomed. Anal., 15 (9-10), (1997),	
		1417-1426	
		KARLSSON, ROBERT, et al., "Experimental Design for Kinetic Analysis of	†
		Protein-Protein Interactions with surface plasmon resonance biosensors",	
		Journal of Immunological Methods, 200, (1997), 121-133	
		KERKELA, E., et al., "Human macrophage metalloelastase (MMP-12)	

EXAMINER DATE CONSIDERED

Substitute for form 1449A/PTO
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as main, sheets as necessary) NOV 2 \$ 2003

Sheet 6 of 9

Application Number	10/601,059	
Filing Date	June 20, 2003	-
First Named Inventor	Yang, Shu-Ping	
Group Art Unit	1646	
Examiner Name	Unknown	

Attorney Docket No: 1443.064US1

	OTHER	DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		expression is induced in chondrocytes during fetal development and malignant transformation", <u>Bone. 29(5)</u> , (2001), 487-493	
		KNAUPER, V., et al., "Biochemical charictorization of human collegenase-3", J. Biol. Chem., 271 (3), (1996), 1544-1550	
		KNOX, J. D., et al., "Matrilysin expression in human prostate carcinoma.", Mol. Carcinog., 15 (1), (1996), 57-63	
		LAKOWICZ, JOSEPH R., "Energy Transfer", Principles of Fluorescence Spectroscopy, Chapter 10,(1983), 303-339	
		LEE, P. P., et al., "Functional role of matrix metalloproteinases (MMPs) in mammmary epithelial cell development", <u>J. Cell Physiol., 188 (1),</u> (2001), 75-88	
		LEVIT, SHIMON, et al., "Ribonucleas S-Peptide", The Jurnal of Biological Chemistry, 251 (5), (1976), 1333-1339	
		LEVY, DANIEL E., "Matrix Metalloproteinase Inhibitors: A Structure-Activity Study", Journal of Medicinal Chemistry, 41, (1998), 199-223	
		LI, J., et al., "Structure of full-length porcine synovial collagenase reveals a C-terminal domain containing a calcium-linked, four-bladed b-propeller", Structure , 3 (6), (1995), 541-549	
		LIBSON, ANDREW M., "Crystal structure of the haemopexin-like C-terminal domain of gelatinase A", Nature Structural Biology, 2 (11), (1995), 938-942	
		LOFAS, STEFAN, "Dextran modified gold for surfaces for surface plasmon resonance sensors: immunoreactivity of immobilized antibodies and antibody-surface interaction studies", Colloids and Surfaces B: Biointerfaces, 1, (1993), 83-89	
		MELCHIORI, A., et al., "Inhibition of tumor cell invasion by a highly conserved peptile", Cancer Res., 58 (8), (1992), 2353-2356	
		MORTON, THOMAS A., "Intetpreting Complex Binding Kinetics from Optical Biosensors: A Comparison of Analysis by Linearization, the Integrated Rate Equation, and Numerical Integration", Analytical Biochemistry, 227, (1995), 176-185	
		MOSES, M. A., "Temporal Study of the Activity of Matrix Metalloproteinases and Their Endogenous Inhibitors During Wound Healing", <u>Journal of Cellular Biochemistry</u> , 60, (1996), 379-386	
		NAGASE, H., et al., "Design and characterization of fluorogenic substrate selectively hydrolyzed by stromelysin 1 (matrix metalloproteinase-3)", <u>J. Biol. Chem.</u> , 269 (33), (1994), 20952-20957	
		O'CONNELL, JAMES P., et al., "Analysis of the role of the COOH-terminal domain in the activation, proteolytic activity, and tissue inhibitor of metalloproteinase interactions of gelatinase B", <u>J. Biol. Chem., 269 (21)</u> , (1994), 14967-14973	
		O'MEARA, S. M., et al., "Systematic review of antimicrobal agents used for	

PTO/SB/08A(10-01)
Approved for use through 10/31/2002, OMB 651-0031
US Petent & Trademark Office: U.S. DEPARTMENT OF COMMERCE
der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO Complete if Known INFORMATION DISCLOSURE **Application Number** 10/601,059 STATEMENT BY APPLICANT (Use as mage sheets as necessary) June 20, 2003 Filing Date Yang, Shu-Ping **First Named Inventor Group Art Unit** 1646 Unknown **Examiner Name** Attorney Docket No: 1443.064US1

	OTHER	DOCUMENTS NON PATENT LITERATURE DOCUMENTS	-
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		chronic wounds", British Journal of Surgery, 88 (1), (2001),4-21	
		O'SHANNESSY, DANIEL J., "Determination of Rate and Equilibrium Binding	
		Constants for Macromolecular Interactions Using Surface Plasmon	
		Resonance: Use of Nonlinear Squares Analysis Methods", Analytical	
		Biochemistry, 212, (1993), 457-468	
		ODAKE, SHINJIRO, "Inhibition of matrix metalloproteinase by peptidyl	
		hydroxamic acids", Biochemical and Biophysical Research Communications,	
		<u>199 (3),</u> (1994), 1442-1446	
		OHTSUKA, Y., et al., "MIP-2 secreted by epithelial cells increases meutophil	
		and lymphocyte recruitment in the mouse instestine", Gut, 49 (4), (2001), 526-533	
		OKADA, Y., et al., "Matrix mettalloproteinase 9 (92-kDa gelatinase/type IV	
		collagenase) from HT 1080 human fibrosarcoma cells", <u>J. Biol. Chem., 267</u>	
		(30), (1992), 21712-21719	
		OLSON, MATTHEW W., "Kinetic Analysis of the Binding of Human Matrix	
		Metalloproteinase-2 and -9 to Tissue Inhibitor of Metalloproteinase (TIMP)-1	
		and TIMP-2", The Journal of Biological Chemistry, 272 (47), (1997), 29975-	
		29983	
		POSTLETHWAITE, ARNOLD E., et al., "Fibrolast Chemoattractants", Methods	
		<u>in Enzymology, 163,</u> (1988), 694-707	
		RAZA, SAADIA L., et al., "Matrix metalloproteinases: Pro and anti-	
		angiogenetic activities", Chemical Abstracts 14-Mammalian Pathological	
		Biochemistry, 135 (4), (2001), 483	
		REINEMER, PETER, "Structural implications for the role of the N terminus in	
		the 'superactivation' of collagenases", <u>FEBS Letters</u> , 338, (1994), 227-233	
		RENIL, MANAT, et al., "Flourescent quenched peptide libraries as tool for	
		identification", Chemical Abstracts 7-Enzymes, 129 (26), (1998), 218	
		SAARIALHO-KERE, U.K., "Patterns of matrix metaloproteinase and TMP	
		expression in chronic ulcers", Archives of Dermatological Research, 290,	
		(1998), \$47-\$54	
		SAKAMOTO, AKIO, et al., "Expression of membrane type 1 matrix	
		metalloproteinase, matrix metalloproteinase 2 and tissue inhibitor of	
		metalloproteinase 2 in human cartilaginous tumors with special emphasis on	
		mesenchymal and dedifferentiated chondrosarcoma", <u>Journal of Cancer</u>	
		Research & Clinical Oncology, 125(10), (1999), 541-548	
		SANG, Q. A., et al., "Activation of Human Progelatinase A by collagenase and matrilysin", J. Protein Chem., 15 (3), (1996), 243-253	
		SAYLE, ROGER A., "RASMOL: biomolecular graphics for all", Trends in	
		Biochemical Sciences, 20, (1995), 333-379	
		SEGEL, IRWIN H., "Kinetics of Unireactant Enzymes", Enzyme Kinetics,	
		<u>Chapter 2,</u> (1975), 18-99	

PTC/SB/08A(10-01)
Approved for use through 10/31/2002. OMB 651-0031
US Patent & Tredemark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1895, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO Complete if Known INFORMATION DISCLOSURE **Application Number** 10/601,059 STATEMENT BY APPLICANT sheets as necessary) June 20, 2003 Filing Date Yang, Shu-Ping **First Named Inventor** NOV 2 4 2003 **Group Art Unit** 1646 Unknown **Examiner Name** Attorney Docket No: 1443.064US1 Sheet 8 of 9

	OTHER	DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		SHAPIRO, S. D., et al., "Activation of the 92-kDa gelatinase by stromelysin	
		and 4-aminophenylmercuric acetate", <u>J. Biol. Chem., 270 (11)</u> , (1995), 6531-	
		6536	
		SODERSTROM, M., et al., "Expression of matrix metalloproteinases and	
		tissue inhibitors of metalloproteinases in human chondrosarcomas", APMIS,	
		<u>109(4)</u> , (2001), 305-315	
		STACK, M. SHARON, et al., "Fluorescence quenching studies of matrix	
		metalloproteinases (MMPs): evidence for structural rearrangement of the	
		proMMP-2/TIMP-2 complex upon mercurial activation", Arch. Biochem.	
		Biophys., 333 (1), (1996), 163-169	
		STAIANO-COICO, LISA, et al., "Wound Fluids: A Reflection of the State of	
		Healing", Ostomy Wound Management, 46, (2000), 85S-93S	ļ
		STETLER-STEVENSON, W. G., et al., "Inhibition of human type IV	
		collagenase by a highly conserved peptide sequence derived from its	
		prosegment", Am. J. Med. Sci., 302 (3), (1991), 163-170	
		STETLER-STEVENSON, W. G., et al., "The activation of human type IV	İ
		collagenase proenzyme", <u>J. Biol. Chem., 264 (3),</u> (1989), 1353-1356	
		SU, JUI-LAN, "Monoclonal Antibodies against Human Collagenase and	
		Stromelysin", <u>Hybridoma, 14 (4), (1995),</u> 383-390	
		TAYLOR, KENNETH B., "The Mechanism of Inhabitation of Collagenase by	
		TIMP-1", The Journal of Biological Chemistry, 271 (39), (1996), 23938-23945	
		TE, KOPPELE, et al., "Method for assaying proteolytic enzymes using	
		flourescence", Chemical Abstracts 7-Enzymes, 127 (11), (1997), 241	
		TUUTTILA, ARI,. "Three-dimensional Structure of Human Tissue Inhibitor of	
		Metalloproteinases-2 at 2.1 A Resolution", <u>Journal of Molecular Biology, 284,</u>	
		(1998), 1133-1140	
	<u> </u>	VAALAMO, MAARIT, "Distinct populations of stromal cells express	
		collagenase-3 (MMP-13) and collagenase-1 (MMP-1) in chronic ulcers but not	
		in normally healing wounds", The Jounal of Investigative Dermatology, 109 (1),	
		(1997), 96-101	
	<u> </u>	VAALAMO, MAARIT, "Patterns of matrix metalloproteinase and TIMP-1	
		expressions in chronic and normally healing human cutaneous wounds",	
		British Journal of Dermatology, 135, (1996), 52-59	
		VERHEIJEN, J. H., et al., "Modified proenzymes as artificial substances for	
		proteolytic", Biochem J., 323, (1997), 603-609	
		WECKROTH, MIINA, "Matrix Metalloproteinases, Gelatinase and	
		Collagenase, in Chronic Leg Ulcers", The Journal of Investigative	
		Dermatology, 106 (5), (1996), 1119-1123	
		WILL, H., et al., "The soluble catalytic domain of membrane type 1 matrix	
		metalloproteinase cleaves the propeptide of progelatinase A and initiates	
		autoproteolytic activation. Regulation by TIMP-2 and TIMP-3", J. Biol. Chem.,	

EXAMINER DATE CONSIDERED

PTO/SB/08A(10-01)
Approved for use through 10/3/1/2020, 20MB 651-0031
US Patient & Trademark Office: U.S. DEPARTMENT OF COMMERCE
I the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO Complete if Known INFORMATION DISCLOSURE 10/601,059 **Application Number** STATEMENT BY APPLICANT (Use as many sheets as necessary) June 20, 2003 **Filing Date** Yang, Shu-Ping **First Named Inventor** NOV 2 4 2003 **Group Art Unit** 1646 Unknown **Examiner Name** Attorney Docket No: 1443.064US1 Sheet 9 of 9

	OTHER	DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		<u>271 (29),</u> (1996), 17119-17123	
-		WOJTOWICZ-PRAGA, SLAWOMIR M., "Matrix Metalloproteinase Inhibitors",	
		Investigative New Drugs, 15, (1997), 61-75	
		WYSOCKI, ANNETTE B., et al., "Wound Fluid From Chronic Leg Ulcers	
		Contains Elevated Levels Of Metalloproteinases MMP-2 and MMP-9", The	
		Journal of Investigative Dermatology, 101 (1), (1993), 64-68	
		WYSOCKI, ANNETTE B., "Wound fluids and the pathogenesis of chronic	
	İ	wounds", Journal of WOCN, 23 (6), (1996), 283-290	